Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 12/20 | 0.69 |
| ▸ | SLC6A4 | P31645 | 12/20 | 0.69 |
| ▸ | HTR1A | P08908 | 11/20 | 0.69 |
| ▸ | SLC6A3 | Q01959 | 8/20 | 0.69 |
| ▸ | HTR6 | P50406 | 4/20 | 0.48 |
| ▸ | HTR2C | P28335 | 4/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5020033 | 0.83 | HTR1A (0.67) | SLC6A2SLC6A4HTR1ASLC6A3HTR6 | |
| SCHEMBL19262554 | 0.81 | SLC6A4 (0.47) | SLC6A2SLC6A4HTR1ASLC6A3HTR6 | |
| SCHEMBL10819398 | 0.80 | SLC6A4 (0.46) | SLC6A2SLC6A4HTR1ASLC6A3HTR6 | |
| SCHEMBL13770273 | 0.78 | HTR1A (0.80) | SLC6A2SLC6A4HTR1ASLC6A3 | |
| SCHEMBL3321425 | 0.77 | SLC6A2 (0.70) | SLC6A2SLC6A4HTR1ASLC6A3HTR6 | |
| SCHEMBL5669748 | 0.75 | SLC6A2 (0.68) | SLC6A2SLC6A4HTR1ASLC6A3HTR6 | |
| SCHEMBL6638482 | 0.74 | HTR2C (0.69) | SLC6A2SLC6A4HTR1ASLC6A3HTR6 | |
| SCHEMBL23228756 | 0.74 | HTR1A (0.59) | SLC6A2SLC6A4HTR1ASLC6A3 | |
| SCHEMBL27794133 | 0.74 | HTR1A (0.55) | SLC6A2SLC6A4HTR1ASLC6A3HTR6 | |
| SCHEMBL31159751 | 0.74 | SLC6A2 (0.61) | SLC6A2SLC6A4HTR1ASLC6A3HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120184525-A1 | 1,2,3-TRIAZOLO [4,3-A] PYRIDINE DERIVATIVES AND THIER USE FOR THE TREATMENT OF PREVENTION OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS | ADDEX PHARMA S.A. (CH) | 2012-07-19 | — | — | US | disclosed |
| WO-2010130424-A9 | 1,2,4-TRIAZOLO [4,3-A] PYRIDINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OR PREVENTION OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS | ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC (US) | 2011-01-27 | — | — | WO | disclosed |
| WO-2010130424-A1 | 1,2,3-TRIAZOLO [4,3-A] PYRIDINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OR PREVENTION OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS | ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC (US) | 2010-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120184525-A1 | 1,2,3-TRIAZOLO [4,3-A] PYRIDINE DERIVATIVES AND THIER USE FOR THE TREATMENT OF PREVENTION OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS | GRM2, GRM3, GRM1 | SLC6A2 177/4885SLC6A4 138/4885HTR1A 41/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.